Structure-Based Design, Synthesis, and Evaluation of Novel Ponatinib Derivatives With a Significantly Altered...

Area of Science:

• Oncology
• Medicinal Chemistry
• Pharmacology

Background:

• Ponatinib is an effective anti-cancer drug, but its use is limited by severe cardiotoxicity due to non-selective kinase inhibition.
• Over 60 kinases are inhibited by ponatinib, contributing to its broad efficacy and significant side effects.

Purpose of the Study:

• To design and synthesize novel ponatinib derivatives with a reduced kinase inhibition spectrum to improve safety.
• To identify compounds that maintain anti-cancer activity while minimizing off-target effects, particularly cardiotoxicity.

Main Methods:

• Structure-based design and synthesis of ponatinib derivatives.
• Modification of the benzamide ring methylation and N-methylpiperazine end group.
• Evaluation of target kinase profiles and in vitro anti-cancer efficacy.

Main Results:

• Compound 5 demonstrated a significantly altered kinase profile, primarily targeting B-Raf and Flt-1.
• Compound 5 no longer inhibited SLK and FGFR1, kinases associated with cardiotoxicity.
• Compound 5 retained significant efficacy in inhibiting MDA-MB-231 breast cancer cell colony formation.

Conclusions:

• Novel ponatinib analogs can be developed with improved pharmacological properties and reduced toxicity.
• Compound 5 represents a promising lead for developing safer and more effective kinase inhibitors.
• Targeted kinase inhibition strategies can mitigate drug-induced side effects in cancer therapy.